Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
Bradley A. Connor, Mara Couto-Rodriguez, Joseph Barrows, Morgan Gardner, Marina Rogova, Niamh B. O’Hara, Dorottya Nagy‐Szakal
Abstract
We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient's symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy.
Topics & Concepts
MedicineTiterMonoclonal antibodyMonoclonal antibody therapyVirologyCoronavirus disease 2019 (COVID-19)AntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Antibody titerSpike ProteinImmunologyInternal medicineDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchViral Infections and Immunology ResearchAnimal Virus Infections Studies